A Business Review Of Calidi Biotherapeutics Inc (AMEX: CLDI) And Growth Forecast

ZM Stock

In the last trading session, 6.43 million shares of the Calidi Biotherapeutics Inc (AMEX:CLDI) were traded, and its beta was 0.93. Most recently the company’s share price was $0.34, and it changed around $0.1 or 39.47% from the last close, which brings the market valuation of the company to $11.56M. CLDI currently trades at a discount to its 52-week high of $3.89, offering almost -1044.12% off that amount. The share price’s 52-week low was $0.20, which indicates that the current value has risen by an impressive 41.18% since then. We note from Calidi Biotherapeutics Inc’s average daily trading volume that its 10-day average is 4.31 million shares, with the 3-month average coming to 793.00K.

Calidi Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CLDI as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.

Calidi Biotherapeutics Inc (AMEX:CLDI) trade information

Instantly CLDI has showed a green trend with a performance of 39.47% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -82.72% year-to-date, but still up 45.65% over the last five days. On the other hand, Calidi Biotherapeutics Inc (AMEX:CLDI) is -6.06% down in the 30-day period. We can see from the shorts that 0.37 million shares have been sold at a short interest cover period of 0.74 day(s).

The consensus price target as assigned by Wall Street analysts is $5.5, which translates to bulls needing to increase their stock price by 93.82% from its current value. Analyst projections state that CLDI is forecast to be at a low of $2 and a high of $9.

Calidi Biotherapeutics Inc earnings are expected to increase by 84.85% in 2025, but the outlook is positive 53.95% per year for the next five years.

CLDI Dividends

Calidi Biotherapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-14.

Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 6.81% of Calidi Biotherapeutics Inc shares, and 17.24% of them are in the hands of institutional investors. The stock currently has a share float of 18.50%. Calidi Biotherapeutics Inc stock is held by 39.0 institutions, with RED WAVE INVESTMENTS LLC being the largest institutional investor. By 2024-06-30, it held 1.1723% of the shares, which is about 0.62 million shares worth $0.12 million.

CPR INVESTMENTS INC., with 1.0511% or 0.56 million shares worth $0.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 353.38 shares worth $0.12 million, making up 0.97% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held roughly 141.47 shares worth around $47392.0, which represents about 0.39% of the total shares outstanding.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.